Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.

In this study, the therapeutic response of topical minoxidil solution was not significantly enhanced by adding topical finasteride, questioning its additional value in treating male pattern androgenetic alopecia.

This article reviews the challenges of treating frontal fibrosing alopecia and the potential role of hair transplantation, noting the lack of effective medical treatments and uncertainty surrounding transplant outcomes.

This review addresses the challenges in treating frontal fibrosing alopecia, highlighting the limited effectiveness of medical treatments and the demand for hair transplantation despite its risks, but it reports no new clinical results.

This chapter reviews the causes, prevalence, and prognosis of androgenetic alopecia and discusses treatments like topical minoxidil and systemic finasteride to stop hair loss and potentially increase hair density.

Rubbing finasteride on the scalp helps with hair loss.

This review explores potential treatments for female androgenetic alopecia, noting that anti-hormonal therapies may be beneficial for some women, but emphasizes the need for further research and effective solutions.

The research shows a potential way to regenerate hair using adult cells that have been grown and guided to produce new hair fibers.

This review discusses natural and botanical products examined for treating alopecia and reports no clinical results; the authors note growing research interest in these treatments.

This study found that both topical and oral finasteride significantly reduced plasma DHT after one week, with lower finasteride plasma exposure for the topical formulation.

This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.

This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.

This commentary explores the challenges and considerations in treating female pattern hair loss, with no new clinical findings reported.

This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.

This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.

In this study, researchers highlighted that while oral valproate often causes hair loss, preliminary experiments with topical valproic acid solution suggest its potential for hair regeneration, potentially offering fewer side effects and reduced cost compared to existing treatments.

This meta-analysis found that the combination of topical minoxidil-finasteride was more effective than minoxidil alone in improving hair density, hair diameter, and global photographic assessment for male androgenetic alopecia, though larger standardized trials are needed to confirm long-term outcomes.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

P-3074 effectively blocks scalp DHT better than oral finasteride.

This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.

This study found that combining topical finasteride with IPL + RF hair removal significantly reduced unwanted facial hair in women after six months compared to placebo.

This phase II study found that a 0.05% topical dutasteride solution was more effective than oral finasteride (1 mg/day) in increasing hair count and width in males with androgenetic alopecia over 24 weeks, without causing irritation.

This study found that using gallate-containing formulations like EGCG or tannic acid increased the solubility and controlled release of finasteride in microspheres, enhancing its dermal penetration in pig skin by 10 to 50 times compared to a control.

This research found that liquid-state liposomes and niosomes may enhance finasteride delivery to pilosebaceous units in hamsters more effectively than gel-state vesicles or hydroalcoholic solution.

This study found that finasteride-loaded liposomal formulations achieved significantly higher skin permeation and deposition compared to conventional gels and solutions, suggesting potential for effective topical application.

This study found that polymeric nanoparticles may effectively deliver finasteride topically to hair follicles, potentially improving alopecia treatment with fewer side effects than oral forms.

This study reports no results yet and only indicates an ongoing randomized placebo-controlled trial investigating the effects of microneedling combined with topical dutasteride solution for treating androgenetic alopecia.

This study found that the MorrF topical solution combination showed significantly better hair growth improvements than Minoxidil alone in male patients with Androgenetic Alopecia.

Two treatments for male pattern hair loss are minoxidil and finasteride, but they have side effects and may not satisfy everyone.

This study found that a 2% topical minoxidil solution significantly increased hair regrowth compared to placebo in women with androgenetic alopecia over 32 weeks.